Literature DB >> 6539224

Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects.

M Aylward, J Maddock, D E Davies, D A Protheroe, T Leideman.   

Abstract

Plasma kinetics of dextromethorphan (as dextrorphan ) and codeine were investigated after acute oral doses in 8 patients with pathological cough; after which the patients participated in an acute dose-response study of the antitussive effects of each drug administered as syrups. Maximum plasma codeine concentrations averaged 384 ng.ml-1 (s.d. +/- 78.3) occurring between 0.75 and 2h after ingestion of 60 mg codeine phosphate; in comparison mean peak plasma dextrorphan levels were 386 ng.ml-1 (s.d. +/- 107.2) and 388 ng.ml-1 (s.d. +/- 101.3) respectively, after administration of 60 mg dextromethorphan syrup and tablet formulations. Bioavailability of dextromethorphan tablets was comparable to syrup. No correlation emerged between instantaneous plasma concentrations of either dextrorphan or codeine and antitussive responses; however, peak antitussive effect was significantly related to log dose with both drugs. Antitussive effects of 30 mg codeine phosphate and 60 mg dextromethorphan hydrobromide did not differ significantly; both were superior to 30 mg dextromethorphan hydrobromide and placebo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6539224

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  12 in total

1.  Codeine and cough: an ineffective gold standard.

Authors:  Donald C Bolser; Paul W Davenport
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-02

2.  Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies.

Authors:  Z R Chen; F Bochner; A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 3.  Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.

Authors:  Donald C Bolser
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

4.  The antitussive effect of dextromethorphan in relation to CYP2D6 activity.

Authors:  R Abdul Manap; C E Wright; A Gregory; A Rostami-Hodjegan; S T Meller; G R Kelm; M S Lennard; G T Tucker; A H Morice
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 5.  Cough hypersensitivity and chronic cough.

Authors:  Kian Fan Chung; Lorcan McGarvey; Woo-Jung Song; Anne B Chang; Kefang Lai; Brendan J Canning; Surinder S Birring; Jaclyn A Smith; Stuart B Mazzone
Journal:  Nat Rev Dis Primers       Date:  2022-06-30       Impact factor: 65.038

6.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

7.  Dextromethorphan pretreatment induces antipyrine clearance in the rat.

Authors:  C K Svensson; J A Ware
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

Review 8.  Appropriate use of antitussives and protussives. A practical review.

Authors:  R S Irwin; F J Curley; F M Bennett
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 9.  Current and future centrally acting antitussives.

Authors:  Donald C Bolser
Journal:  Respir Physiol Neurobiol       Date:  2006-03-06       Impact factor: 1.931

Review 10.  Currently available cough suppressants for chronic cough.

Authors:  Kian Fan Chung
Journal:  Lung       Date:  2007-10-02       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.